Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HemCon Medical Technologies, a developer of advanced medical products, has signed a new collaborative development agreement with ProMetic Life Sciences's UK-based division, ProMetic BioSciences, which is engaged in the development of separation products and technologies for use in the manufacturing of biopharmaceutical products.
Subscribe to our email newsletter
Together, HemCon and ProMetic will develop and validate a sterile, single-use antibody capture device for the removal of isoagglutinin antibodies.
The exclusive agreement covers the development of a new capture device, based on ProMetic’s affinity adsorbent technology, for both single source and pooled plasma in combination with the HemCon lyophilized plasma (LyP) system currently under development.
Under the terms of the agreement, the development program will be funded by HemCon and both companies will jointly own all collaboration technology for the new device that is intended for the LyP system. In addition, HemCon will have exclusive purchasing rights for the device and ProMetic will be its sole supplier for the LyP system.
John Morgan, CEO of HemCon, said: “HemCon is pleased to collaborate with ProMetic to develop this innovative capture device. ProMetic has worked with many influential companies and organizations, including the American Red Cross, to ensure the purification of blood, plasma and plasma-derived products. As we continue to develop our new LyP system, ProMetic’s technology will help us broaden our donor supply pool and increase the resuscitation fluid options for our military and civilian customers.”